GLP-1 Agonists May Reduce Oral Contraceptive Effectiveness

GLP-1 receptor agonists have surged in popularity as treatments for obesity and type 2 diabetes, with millions of women of reproductive age now using medications like semaglutide and tirzepatide. A key pharmacological effect of these drugs is delayed gastric emptying, which slows the movement of food and medications through the digestive tract. This raises an important clinical question: could GLP-1 agonists interfere with the absorption of oral contraceptive pills?

The Faculty of Sexual and Reproductive Healthcare (FSRH) addressed this concern in a February 2025 statement, which is summarized in this Drug and Therapeutics Bulletin overview. The FSRH evaluated the potential for GLP-1 agonists to impair the bioavailability of ethinylestradiol and progestin-based oral contraceptives by slowing their gastrointestinal absorption.

While direct clinical trial data on this specific interaction remain limited, the mechanistic concern is well-founded. Delayed gastric emptying is a class effect of GLP-1 agonists and has been shown to affect absorption of other orally administered drugs. Nausea and vomiting, common side effects especially during GLP-1 dose escalation, may further compromise contraceptive pill absorption if vomiting occurs shortly after ingestion.

The practical implication is significant: women using oral contraceptives who begin GLP-1 agonist therapy may face reduced contraceptive efficacy, potentially increasing unintended pregnancy risk. Healthcare providers are encouraged to discuss this interaction proactively and consider recommending non-oral contraceptive alternatives, such as intrauterine devices, implants, or injectable methods, which bypass the gastrointestinal absorption issue entirely.

Caveats include the limited availability of direct pharmacokinetic interaction data specific to oral contraceptives and GLP-1 agonists. The guidance is precautionary and based largely on mechanistic reasoning. Further clinical studies are needed to quantify the magnitude of any absorption reduction and its real-world contraceptive impact.